CRGC-B showed a tumor-infiltrating lymphocyte environment that was more conducive to immunotherapy, including extensive infiltration by CD8+ T cells and CD4+ T cells, as well as enrichment of M1/M2 macrophages. The gene discussed is CD8A; the disease is neoplasm.